These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19581612)

  • 1. Rational use of medications: if Canada can't do it ..
    Califf RM
    CMAJ; 2009 Jul; 181(1-2):15-6. PubMed ID: 19581612
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term trends in use of and expenditures for cardiovascular medications in Canada.
    Jackevicius CA; Cox JL; Carreon D; Tu JV; Rinfret S; So D; Johansen H; Kalavrouziotis D; Demers V; Humphries K; Pilote L;
    CMAJ; 2009 Jul; 181(1-2):E19-28. PubMed ID: 19581604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Would a national pharmaceutical strategy be bad for the cardiovascular health of Canadians?
    Tu JV
    Can J Cardiol; 2007 Jul; 23(9):719-20. PubMed ID: 17622394
    [No Abstract]   [Full Text] [Related]  

  • 4. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001.
    Jackevicius CA; Tu K; Filate WA; Brien SE; Tu JV;
    Can J Cardiol; 2003 Nov; 19(12):1359-66. PubMed ID: 14631469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Canadian Cardiovascular Society.
    Can J Cardiol; 1997 Jan; 13(1):33-45. PubMed ID: 9039063
    [No Abstract]   [Full Text] [Related]  

  • 6. Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of available ones.
    Shantsila A; Lip GY
    Int J Clin Pract; 2010 Jan; 64(2):138-40. PubMed ID: 20089004
    [No Abstract]   [Full Text] [Related]  

  • 7. The Canadian Cardiovascular Society and reference-based drug pricing.
    Olley PM; McLaughlin PR
    Can J Cardiol; 1998 May; 14(5):669-70. PubMed ID: 9627521
    [No Abstract]   [Full Text] [Related]  

  • 8. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
    Khatib R; McKee M; Shannon H; Chow C; Rangarajan S; Teo K; Wei L; Mony P; Mohan V; Gupta R; Kumar R; Vijayakumar K; Lear SA; Diaz R; Avezum A; Lopez-Jaramillo P; Lanas F; Yusoff K; Ismail N; Kazmi K; Rahman O; Rosengren A; Monsef N; Kelishadi R; Kruger A; Puoane T; Szuba A; Chifamba J; Temizhan A; Dagenais G; Gafni A; Yusuf S;
    Lancet; 2016 Jan; 387(10013):61-9. PubMed ID: 26498706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.
    LeLorier J; Rawson NS
    Can J Cardiol; 2007 Jul; 23(9):711-8. PubMed ID: 17622393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Underutilization of cardiovascular pharmacotherapy: how to pay for it?].
    Wehling M
    Dtsch Med Wochenschr; 2004 Feb; 129(7):330. PubMed ID: 14765334
    [No Abstract]   [Full Text] [Related]  

  • 11. The cost effectiveness of cardiovascular medicines.
    Hay J
    Curr Atheroscler Rep; 2005 Mar; 7(2):79-80. PubMed ID: 15727719
    [No Abstract]   [Full Text] [Related]  

  • 12. The Imminent Demise of Cardiovascular Drug Development.
    Packer M
    JAMA Cardiol; 2017 Dec; 2(12):1293-1294. PubMed ID: 29117286
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacoeconomics and cardiovascular disease].
    Anguita Sánchez M
    Rev Clin Esp; 2004 Aug; 204(8):391-2. PubMed ID: 15274760
    [No Abstract]   [Full Text] [Related]  

  • 14. Universal access to medicines.
    Niessen LW; Khan JA
    Lancet; 2016 Jan; 387(10013):9-11. PubMed ID: 26498705
    [No Abstract]   [Full Text] [Related]  

  • 15. I am considering using an on-line pharmacy to get my heart medications at less cost. Are there any drawbacks with this?
    Heart Advis; 2010 Jul; 13(7):8. PubMed ID: 23091868
    [No Abstract]   [Full Text] [Related]  

  • 16. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics.
    Califf RM
    Am Heart J; 1999 May; 137(5):S35-7. PubMed ID: 10220593
    [No Abstract]   [Full Text] [Related]  

  • 17. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
    Detsky AS
    Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cardiovascular pharmacotherapy in old age: How beneficial is it? What does it cost?].
    Gysling E
    Praxis (Bern 1994); 1995 Oct; 84(44):1248-51. PubMed ID: 7491446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reference-based pricing of prescription drugs.
    McLaughlin PR
    Can J Cardiol; 1997 Jan; 13(1):31-2. PubMed ID: 9039062
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prescription drug atlas 2008--prescription drug utilization in the German national health insurance. The sick patient as a business machine].
    Aumiller J
    MMW Fortschr Med; 2008 Oct; 150(41):7. PubMed ID: 19013836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.